Skip to contentM
Myriad Genetics Inc
M
MYGNMyriad Genetics Inc Q4 2015 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$189.30M$189.30Mderived+0.3% vs Q4 2014 Net Income$18.40M$18.40Mderived−45.2% vs Q4 2014 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Myriad Genetics Inc · CIK 899923 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$35,700,000−32.9% Operating Cash Flowderived$51,000,000+24.6% Free Cash Flowderived$49,000,000+35.1% Margins · derivedOperating margin18.9%−9.3 pt vs Q4 2014
Net margin9.7%−8.1 pt vs Q4 2014
ended Jun 30, 2015 · filed Aug 12, 2015 · 43 d after period end